Understanding Cardiotoxicity Risk with BTK Inhibitors in Hematologic Cancers: Muhammad Salman Faisal, MBBS

At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Muhammad Salman Faisal, third-year Hematology/Oncology Fellow at Roswell Park Comprehensive Cancer Center, sat down to discuss his poster on “Risk Assessment of Cardiovascular Adverse Events with Bruton Tyrosine Kinase (BTK) Inhibitors in Hematological Malignancies: Insights from FAERS.” In this discussion with coauthor Dr. Karan Jatwani, Dr. Faisal elaborates on the research, including:

  • The role of BTK inhibitors—ibrutinib, acalabrutinib, and zanubrutinib—in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas, including mantle cell lymphoma, diffuse large B-cell lymphoma, and lymphoplasmacytic lymphoma
  • Their study investigating the pharmacovigilance, reporting rate, severity, and reaction outcomes of cardiovascular toxicity with BTK inhibitors as reported to the US Food and Drug Administration Adverse Event Reporting System (FAERS)
  • The prevalence of cardiac arrythmia, major coronary or vascular event (MACE), and pericardial complications found in the database
  • The implication of these results for patient selection and toxicity management for BTK inhibitors in hematologic malignancies
  • And more!

This interview is also available as a podcast. Click here to listen! 

About Dr. Faisal

Muhammad Salman Faisal, MBBS, is a third-year Hematology/Oncology Fellow at Roswell Park Comprehensive Cancer Center in Buffalo, New York. His research interests include stem cell transplantation and cellular therapies for improving outcomes in hematologic malignancies. Dr. Faisal is the founder of the Heme-Onc Fellows Network and a member of the ASCO Trainee Council.

Banner ad

Related Articles

Responses

Your email address will not be published. Required fields are marked *